Publications by authors named "J C Bures"

We assessed the diagnostic performance of the Narrow-Band Imaging (NBI) International Colorectal Endoscopic Classification (NICE) and the Japan NBI Expert Team classification (JNET) in predicting histological outcomes of advanced colorectal lesions. Additionally, we evaluated the sensitivity and positive predictive value (PPV) of the JNET and NICE classifications individually for high-grade lesions (including HGD adenomas, intramucosal carcinomas, and T1 carcinomas). This was a retrospective analysis of prospectively collected data, involving 211 patients (130 men, mean age 60 years) who underwent colonoscopy with endoscopic resection of advanced colorectal neoplasia (lesions ≥ 10 mm).

View Article and Find Full Text PDF

Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. It also exerts antagonising activity against -methyl-D-aspartate receptors. Tacrine was approved for the treatment of Alzheimer's disease in 1993, but was withdrawn from clinical use in 2013 because of its hepatotoxicity and gastrointestinal side effects.

View Article and Find Full Text PDF
Article Synopsis
  • Severe alcohol-associated hepatitis (SAH) is a serious condition with high mortality rates, and current treatments like corticosteroids have limited effectiveness, prompting the exploration of new therapies such as fecal microbiota transplantation (FMT).
  • This study aimed to investigate the impact of FMT on 30- and 90-day mortality in SAH patients who did not respond to or were ineligible for corticosteroids, as well as to identify outcomes and factors influencing patient survival.
  • The research involved a prospective analysis of adult patients receiving FMT, comparing their outcomes with a control group who received standard care, and evaluating various prognostic factors related to SAH outcomes.
View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis, with near-identical incidence and mortality. According to the World Health Organization Globocan Database, the estimated number of new cases worldwide will rise by 70% between 2020 and 2040. There are no effective screening methods available so far, even for high-risk individuals.

View Article and Find Full Text PDF